Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Genitourinary 1Breast 1

Conditions

Leukemia, Myeloid, Acute 57Anemia, Refractory, with Excess of Blasts 48Myelodysplastic Syndromes 44Venous Thromboembolism 32Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Anemia, Aplastic 26Myeloproliferative Disorders 25Lymphoma, Non-Hodgkin 23Neoplasms 22Multiple Myeloma 21Leukemia, Myelogenous, Chronic, BCR-ABL Positive 20Anemia 20Hodgkin Disease 19Thrombocytopenia 18Primary Myelofibrosis 18Leukemia, Myelomonocytic, Chronic 18Leukemia, Lymphocytic, Chronic, B-Cell 18Leukemia 18Hematologic Neoplasms 17Lymphoma 15Anemia, Sickle Cell 13Lymphoma, Follicular 11Fanconi Anemia 11Cytopenia 11Venous Thrombosis 10Febrile Neutropenia 10Bone Marrow Failure Disorders 10Pulmonary Embolism 9Leukemia, Biphenotypic, Acute 9Polycythemia Vera 8

Interventions

olaparib 2Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fanconi Anemia, Complementation Group D1 × Classical hematology × 1 year × Clear all
NCT03344965 2026-01-05

Olaparib In Metastatic Breast Cancer

Beth Israel Deaconess Medical Center

Phase 2 Active not recruiting
114 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT04038502 2025-08-20

COBRA

VA Office of Research and Development

Phase 2 Recruiting
100 enrolled
Classical hematologyGenitourinary

Fanconi Anemia, Complementation Group N, Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡